UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-38198 ...

Clinical Trials and Product Development - The company completed a Phase 1 clinical trial for its lead product candidate PGN-EDO51 in healthy volunteers, achieving over 70% exon 51 skipping in non-human primate studies[90] - The company plans to initiate two parallel Phase 2 studies for PGN-EDO51 in DMD patients in 2023, with initial data expected in 2024[90] - PGN-EDODM1 is anticipated to enter a Phase 1 clinical trial in DM1 patients in the first half of 2023, with results expected in 2024[92] - The company is developing additional EDO therapeutics targeting other DMD exon skipping populations and anticipates advancing more programs into clinical studies in 2024[93] Financial Performance - The company reported net losses of $16.3 million and $18.2 million for the three months ended March 31, 2023, and March 31, 2022, respectively[97] - Total operating expenses for Q1 2023 were $18.0 million, compared to $13.9 million in Q1 2022, reflecting an increase of $4.1 million[113] - Net loss for Q1 2023 was $16.3 million, a decrease of $1.9 million compared to a net loss of $18.2 million in Q1 2022[113] - Cash and cash equivalents as of March 31, 2023, were $165.4 million, with an accumulated deficit of $119.2 million[97] - Cash and cash equivalents as of March 31, 2023, amounted to $165.4 million, expected to fund operations into early 2025[119] - Net cash used in operating activities for Q1 2023 was $15.4 million, compared to $12.3 million in Q1 2022[123] Research and Development Expenses - Research and development expenses for the three months ended March 31, 2023, totaled $14.36 million, compared to $10.71 million for the same period in 2022, reflecting an increase in clinical trial activities[103] - Research and development expenses increased by $3.7 million from $10.7 million in Q1 2022 to $14.4 million in Q1 2023, driven by clinical program advancements and increased personnel costs[114] General and Administrative Expenses - General and administrative expenses rose by $0.5 million from $3.2 million in Q1 2022 to $3.7 million in Q1 2023, primarily due to higher personnel-related costs[115] Capital and Funding - The company raised approximately $122.9 million in gross proceeds from its IPO, with net proceeds of $110.2 million after deducting underwriting discounts and offering expenses[94] - The company has raised a total of $163.9 million from the sale of common and convertible preferred stock since inception[118] - Future capital requirements will depend on various factors, including the costs and timing of clinical trials and regulatory reviews[120] Revenue and Taxation - The company has not generated any revenue from product sales since inception and expects to continue incurring significant operating losses[96] - The company has not recorded a U.S. provision for federal or state income taxes due to no revenue and incurred losses since inception[112] - Interest income for Q1 2023 was $1.8 million, significantly up from $0.1 million in Q1 2022, primarily due to cash deposits and US Treasury-backed money market funds[116]

PepGen Inc (NASDAQ:PEPG) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Noel Donnelly - Chief Financial Officer James McArthur - President and Chief Executive Officer Jaya Goyal - Executive Vice President, Research and Preclinical Development Michelle Mellion - Senior Vice President and Head, Clinical Development Conference Call Participants Laura Chico - Wedbush Operator Good afternoon and welcome to the PepGen Conference Call to discuss PepGen’s Fourth Quarter and Full Yea ...

NT T NT T NT T 0 100 200 300 400 Pcolce/Rplp0 (normalized to control) Untreated DM1 control 2 wks 12 wks 24 wks Protocol: PGN-EDODM1 was administered once intravenously (IV) to HSALR mice at 30 mg/kg; quadriceps muscle harvested 2, 12 or 24 weeks postadministration; graph plotted as mean ± SD; n=7 for 0 timepoint, 8 for 2- and 12-week timepoints; 5 for 24-week timepoint. Transcript levels measured by qPCR and normalized to Rplp0. NT = not treated. NHP: IND-ENABLING STUDIES DOSED THROUGH 90 MG/KG, RESULTS SU ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________________ TO _____________________ Commission File Number 001-41374 Indicate by check mark whether the Registrant has submitted electronically every In ...

EMPOWERING OLIGONUCLEOTIDE THERAPEUTICS Any forward-looking statements in this presentation are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete preclinical studies and cl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-3819886 (State or other jurisdiction of incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-38198 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-3819 ...